Pictured: AstraZeneca office in Gothenburg, Sweden/iStock, Wirestock AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational oral glucagon-like peptide 1 receptor agonist that is being developed for obesity, type 2 diabetes and other cardiometabolic diseases
Current medicinal chemistry , 31 (29), 4579-4601
Rising use of GLP-1 agonists across common orthopaedic procedures and their association with improved postoperative outcomes by Haque, H., et al Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study by Johnson, B., et al Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis by Karakasis, P., et al GLP-1 receptor agonists and sarcopenia: Weight loss at a cost
Whether you're looking to brighten your complexion, reduce fine lines, or simply rejuvenate your skin, glutathione injections offer a safe and affordable solution
65 Campbell, A., Heydarian, R., Ochoa, C., Dwivedi, A